Product apis-dna-damage-dna-repa

Home > products > apis> dna-damage-dna-repa

Catalog	name	Description	price
R-R-4460	DB0614 CAS No.2769753-47-9	DB0614 (Example 21)/CAS No.2769753-47-9 is a bifunctional compound targeted protein degradation of kinases. DB0614 degrades AAK1, AURKA, BMP2K, CAMKK1, CDK16, CML, CDK6, EIF2AK2, FER, GAK, LCK, LIMK2, MAP3KH, MAPK8, MAPK9, NEK9, PLK4, PTK2B, SIK2, STK17A, STK17B, ULK1, ULK3, and WEE1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity.	price>
R-R-4461	ENMD-2076 Tartrate CAS No.1453868-32-0	ENMD-2076 Tartrate/CAS No.1453868-32-0 is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.	price>
R-R-4462	CCT241736 CAS No.1402709-93-6	CCT241736/CAS No.1402709-93-6 is a potent and orally bioavailable dual FLT3 and Aurora kinase inhibitor, which inhibits Aurora kinases (Aurora-A Kd, 7.5 nM, IC50, 38 nM; Aurora-B Kd, 48 nM), FLT3 kinase (Kd, 6.2 nM), and FLT3 mutants including FLT3-ITD (Kd, 38 nM) and FLT3(D835Y) (Kd, 14 nM).	price>
R-R-4463	Aurora kinase inhibitor-3 CAS No.879127-16-9	Aurora kinase inhibitor-3/CAS No.879127-16-9 is a strong and selective Aurora A kinase inhibitor with an IC50 of 42 nM, and weakly inhibits EGFR with an IC50 of >10 μM. Aurora kinase inhibitor-3 has a binding mode with the cyclopropanecarboxylic acid moiety directed towards the solvent exposed region of the ATP-binding pocket.	price>
R-R-4464	dAURK-4 hydrochloride	dAURK-4 hydrochloride, an Alisertib derivative, is a potent and selective AURKA (Aurora A) degrader. dAURK-4 hydrochloride has anticancer effects.	price>
R-R-4465	AKI603 CAS No.1432515-73-5	AKI603/CAS No.1432515-73-5 is an inhibitor of Aurora kinase A (AurA), with an IC50 of 12.3 nM. AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells.	price>
R-R-4466	Tinengotinib CAS No.2230490-29-4	Tinengotinib/CAS No.2230490-29-4 is the modulator of one or more protein kinases such as Aurora kinase and VEGFR kinase. Tinengotinib has the potential for the research of these kinase abnormalities diseases mediated, especially cancer-related diseases (extracted from patent WO2018108079A1).	price>
R-R-4467	Aurora kinase inhibitor-8 CAS No.2133001-88-2	Aurora kinase inhibitor-8/CAS No.2133001-88-2 is a highly selective inhibitor of the Aurora kinases.	price>
R-R-4468	TC-A 2317 hydrochloride CAS No.1245907-03-2	TC-A 2317 hydrochloride/CAS No.1245907-03-2 is an orally active Aurora A kinase inhibitor (Ki=1.2 nM). TC-A 2317 hydrochloride exhibits excellent selectivity to Aurora B kinase (Ki=101 nM) and other 60 kinases, good cell permeability and good PK profile. Antitumor activity.	price>
R-R-4469	Aurora Kinases-IN-3 CAS No.2840558-83-8	Aurora Kinases-IN-3 (Compound 15a)/CAS No.2840558-83-8 is an orally active AURKB inhibitor that elicits an AURKB-suppressive activity by disrupting the mitotic localization of AURKB, rather than inhibiting its phosphorylation of H3 at Ser10.	price>

...